Skip to main content

Dalio Center for Health Justice Home

NewYork-Presbyterian

Dalio Center for Health Justice

Sickle Cell versus Healthy Cell

Sickle Cell Disease

Sickle Cell Disease is an inherited blood disorder that predominantly affects Black people. In the US, sickle cell disease occurs in approximately 1 out of every 365 Black or African-American births. Sickle Cell Disease has long been neglected, resulting in limited improvement in mortality in the last four decades. However, exciting new technologies and medicines with great potential are currently being studied to combat the disease. Our new enterprise-wide program aims to provide innovative, compassionate, patient-centered care.

Areas of focus include:

  • Standardizing clinical pathways
  • Expanding access to virtual care
  • Providing seamless transitions from pediatric to adult care
  • Enhancing access to advanced therapies
  • Supporting multi-center clinical trials
  • Increasing awareness about sickle cell disease. Learn more.

Dalio Center for Health Justice Work

At the Dalio Center for Health Justice, we follow a set of core initiatives aimed to help us optimize care and patient experience for those with Sickle Cell Disease.

These include:

Care Optimization

  • Using electronic medical records to standardize care and improve communication between healthcare providers
  • Supporting a clinical workgroup to develop best practice
  • Investing in the transition from pediatric to adult care
  • Analyze key patient metrics
  • Creating sickle cell-specific patient registries to assess patient progress

Patient Experience

  • Improving patient and caregiver education and resources
  • Investing in education for healthcare providers
  • Hosting patient experience days and educational symposia

NYP Pediatric Sickle Cell Disease
NYP Adult Blood Disorders
NYP Brooklyn Methodist Sickle Cell and Thalassemia Diseases
Columbia University Irving Medical Center Children's Health Sickle Cell Disease
Weill Cornell Medicine Center for Blood Disorders

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia- NEJM
Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease- NEJM
Acupuncture for pediatric sickle cell pain management: A promising non-opioid therapy
Greater number of perceived barriers to hydroxyurea associated with poorer health-related quality of life in youth with sickle cell disease
Quality of Life of Latino and Non-Latino Youth With Sickle Cell Disease as Reported by Parents and Youth
Food insecurity, housing instability, and dietary quality among children with sickle cell disease: Assessment from a single urban center
Are We About to Cure Sickle-Cell Disease?